Tons of press coverage for this morning's Government Accountability Office report criticizing the Food and Drug Administration's safety system. Much of the critique hinged on three easily rectifiable problems: a lack of independence for the too small safety office (its paltry staff is currently housed within the new drug approval division); a lousy post-marketing monitoring system; and a lack of resources. In other words, the FDA cannot fix its own problems. Only Congress, which controls the purse strings and the agency's legislative authority, has that power.
Bottom line: If you're worried about drug safety, remember to vote this November.
I was intrigued by one comment, though, which was contained in the Washington Post coverage. Caroline Loew, senior vice president of the Pharmaceutical Research and Manufacturers of America (PhRMA, the industry trade group), defended the FDA's record by saying only 3 percent of all aproved drugs were later withdrawn for safety reasons.
Hmmm. What other industry is proud of a 3 percent defective rate? Automakers or electronics equipment manufacturers, who expect 6 sigma quality from their suppliers? (That's 3.4 errors per million or 3.4 ten-thousandths of a percent.) Your favorite local restaurant? (Hey, you can't shut us down. Only 3 percent of our customers got food poisoning last week). How about the kid who mows the lawn? Okay, if he gets 97 percent of the grass, I'm satisfied.
Posted by gooznews at April 24, 2006 10:37 PMWhat most people don't know is that while pharmaceutical companies MUST complete Phase I, II and III studies before a drug can be approved and marketed, the Phase IV study is post-market, and the uninformed patients using a new drug form the base for the "study." But since no actual data is required from the pharmaceutical company, the VOLUNTARY MedWatch (adverse event reporting system) reports comprise the final interface between the public and the pharmaceutical.
Notice that this is a VOLUNTARY reporting system. Many doctors do not even know of its existence, and those who do, fear the paperwork nightmare a report creates. Patient reports are discounted as "anecdotal" and given little credence. And the system is so arcane that any "numbers" generated are meaningless. This method of Phase IV testing suits Big Pharma ideally. You can bet they will be lobbying against any change to the current methodology. And as you said, Congress must initiate funding for any meaningful change to occur. How about a surtax on drugs to fund this aftermarket watchdog program?